Literature DB >> 8957239

Interaction of the macrolide azithromycin with phospholipids. II. Biophysical and computer-aided conformational studies.

J P Montenez1, F Van Bambeke, J Piret, A Schanck, R Brasseur, P M Tulkens, M P Mingeot-Leclercq.   

Abstract

In a comparison paper, we show the azithromycin causes a lysosomal phospholipidosis in cultured cells, binds in vitro to negatively charged bilayers without causing aggregation or fusion, and inhibits lysosomal phospholipase A1. In this paper, we show that azithromycin decreases the mobility of the phospholipids in negatively charged liposomes (using 31P nuclear magnetic resonance) and that it increases the fluidity of the acyl chains close to the hydrophilic/hydrophobic interface, but not deeper into the hydrophobic domain (assessed by measuring the fluorescence polarization of trimethylammonium-diphenylhexatriene and diphenyhexatriene, respectively). Computer-aided conformational analysis of mixed monolayers of azithromycin and phosphatidylinositol shows that the drug can be positioned largely in the hydrophobic domain, but close to the interface, with the macrocycle facing the C1 of the fatty acids (allowing the N9a endocyclic tertiary amine to interact with the phospho-groups), the cladinose located on the hydrophobic side of the lipid/water interface and the desosamine projected into the hydrophobic domain. This position is consistent with the experimental data. Analysis of virtual molecules shows that this unanticipated behavior to the shielding of the ionizable N3' amino-group in the desosamine by methyl-groups, and to the wide dispersion of hydrophobic domains all over the molecule. The interaction of azithromycin with phospholipids may account for some of its unusual pharmacokinetic properties and for its potential to cause lysosomal phospholipidosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8957239     DOI: 10.1016/s0014-2999(96)00553-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.

Authors:  Songmao Zheng; Peter Matzneller; Markus Zeitlinger; Stephan Schmidt
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

2.  Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils.

Authors:  Sandrine Lemaire; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

Review 3.  Azithromycin use in patients with cystic fibrosis.

Authors:  N Principi; F Blasi; S Esposito
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-02-17       Impact factor: 3.267

4.  Interaction of the macrolide antibiotic azithromycin with lipid bilayers: effect on membrane organization, fluidity, and permeability.

Authors:  A Berquand; N Fa; Y F Dufrêne; M P Mingeot-Leclercq
Journal:  Pharm Res       Date:  2005-03       Impact factor: 4.200

5.  Experimental and conformational analyses of interactions between butenafine and lipids.

Authors:  M P Mingeot-Leclercq; X Gallet; C Flore; F Van Bambeke; J Peuvot; R Brasseur
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

6.  Cell handling, membrane-binding properties, and membrane-penetration modeling approaches of pivampicillin and phthalimidomethylampicillin, two basic esters of ampicillin, in comparison with chloroquine and azithromycin.

Authors:  Hugues Chanteux; Isabelle Paternotte; Marie-Paule Mingeot-Leclercq; Robert Brasseur; E Sonveaux; Paul M Tulkens
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

7.  The macrolide antibiotic azithromycin interacts with lipids and affects membrane organization and fluidity: studies on Langmuir-Blodgett monolayers, liposomes and J774 macrophages.

Authors:  D Tyteca; A Schanck; Y F Dufrêne; M Deleu; P J Courtoy; P M Tulkens; M P Mingeot-Leclercq
Journal:  J Membr Biol       Date:  2003-04-01       Impact factor: 1.843

8.  Pharmacokinetics of tulathromycin in healthy and neutropenic mice challenged intranasally with lipopolysaccharide from Escherichia coli.

Authors:  N Villarino; S A Brown; T Martín-Jiménez
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

9.  Highly Sensitive Electrochemical Detection of Azithromycin with Graphene-Modified Electrode.

Authors:  Florina Pogăcean; Codruţa Varodi; Lidia Măgeruşan; Raluca-Ioana Stefan-van Staden; Stela Pruneanu
Journal:  Sensors (Basel)       Date:  2022-08-18       Impact factor: 3.847

10.  Influence of Pyrexia on Pharmacokinetics of Azithromycin and Its Interaction With Tolfenamic Acid in Goats.

Authors:  Sini Mechery; Suresh Narayanan Nair; Thirumangalath Meethal Divya; Kanjirakuzhiyil Promod; Sakkariya Ibrahim Nalukudy Paramba; Reghu Ravindran; Sanis Juliet
Journal:  Front Vet Sci       Date:  2021-06-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.